Medical Economics October 4, 2024
Medicare’s restrictive coverage policies are denying patients with early Alzheimer’s disease access to novel treatments. And private payers are following suit.
In August, on the same day the United Kingdom’s health regulator approved a new treatment for Alzheimer’s disease, the country’s cost-effectiveness regulator recommended nixing national coverage for it.
Since new Alzheimer’s disease treatments are available only to patients in the early stages of the disease, the potential impact on geriatricians, family doctors and other primary care physicians, who are responsible for approximately 85% of initial dementia diagnoses, cannot be overstated. In fact, when the proposed noncoverage policy from the National Institute for Health and Care Excellence (NICE) for the drug, called Leqembi, is finalized this fall, an estimated 70,000...
Today's Sponsors
Today's Sponsor